You are here
JFDA affirms effectiveness of AstraZeneca COVID vaccine
By JT - Apr 01,2021 - Last updated at Apr 01,2021
This photo shows vials of the AstraZeneca COVID-19 vaccine and a syringe in Paris on March 11, 2021 (AFP photo)
AMMAN — The AstraZeneca vaccine showed efficacy in reducing hospital admissions and COVID-19 fatalities, the Jordan Food and Drug Administration (JFDA) said on Thursday.
JFDA Director General Nizar Mheidat, in a statement, said that a total of 144,000 AstraZeneca jabs have been administered in Jordan and no unexpected side effects have been reported. He stressed that all medical notes reported after administering the AstraZeneca vaccine were common side effects “with nothing unusual”, the Jordan News Agency, Petra, reported.
The UK, Australia, Italy, France, Spain, Portugal, among others, continue using the AstraZeneca COVID-19 vaccine, as the rate of blood clotting following vaccination with AstraZeneca's COVID-19 vaccine does not exceed 0.0000015 per cent, a tiny percentage that does not necessitate the suspension of the vaccine, Mheidat added.
Related Articles
AMMAN — The Jordan Food and Drug Administration (JFDA) said on Monday that the administration approved the emergency use of the Johnson &
AMMAN — The Kingdom on Friday received the first shipment of the AstraZeneca/SK Bioscience COVID vaccine, consisting of 144,000 doses, from
GENEVA — The World Health Organisation said there was no reason to stop using AstraZeneca's COVID-19 jab after several countries suspended r
Opinion
Nov 20, 2024
- Popular
- Rated
- Commented
Nov 20, 2024
Newsletter
Get top stories and blog posts emailed to you each day.
